Dihydropyrimidinase Polyclonal Antibody, PE-Cy5.5 Conjugated
Product Specifications
Background
Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD) . DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy.
Synonyms
DHP; DHPase; Dihydropyrimidinase; Dihydropyrimidine amidohydrolase; Dpys; DPYS_HUMAN; Hydantoinase.
Gene ID
1807
Cellular Locus
Cytoplasm, Secreted, Extracellular matrix
Host
Rabbit
Immunogen
121-220/519
Target
Dihydropyrimidinase
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy5.5
Source
KLH conjugated synthetic peptide derived from human DHP/Dihydropyrimidinase
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
488nm/694nm
Concentration
1µg/µl
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
1807
Predicted Cross Reactivity
Human, Mouse, Rat, Dog, Cow, Sheep, Chicken
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
